Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. (Q42725709)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Niccola Funel

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Maurizio Lucchesi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

11

Godefridus J Peters

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Paola Pacetti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Michele Reni

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Leticia G Leon

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Andrea Mambrini

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Enrico Vasile

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Michele Ghidini

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Stefano Cereda

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Maurizio Cantore

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

25 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

1641-1652

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22026922%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Advanced pancreatic carcinoma: current treatment and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Gemcitabine resistance in pancreatic cancer: picking the key players

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Pharmacogenomics in non-small-cell lung cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Assessing the probability that a positive report is false: an approach for molecular epidemiology studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Basis for effective combination cancer chemotherapy with antimetabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109

Detecting pathway-based gene-gene and gene-environment interactions in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.109